...
首页> 外文期刊>International Urology and Nephrology >Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully
【24h】

Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully

机译:用于治疗耐药尿路感染的福赛霉素:迫使旧药物的潜力完全探讨

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Introduction Increased emergence of bacterial resistance and the limited options of novel antimicrobial agents have necessitated the reintroduction of some old antimicrobial agents. One such drug is fosfomycin, but its potential has not been explored fully, especially in India. Aims and objectives To analyze the in vitro activity of fosfomycin, against the urinary isolates and to compare it with in vitro activity of other orally administered antimicrobial agents. Materials and methods This was a prospective observational study conducted between July 2014 and June 2016. All consecutive, non-duplicate and clinically significant urinary isolates obtained from patients of all ages and both genders, diagnosed to have UTI, were included. Patients already on antibiotic therapy were excluded. Urine culture was performed by semiquantitative method on cysteine lactose electrolyte-deficient medium and the isolates obtained in significant count were subjected to antimicrobial sensitivity testing by the Kirby Bauer disk diffusion method as per CLSI guidelines. Results A total of 3947 non-repeating urinary isolates were included in the study, of which 2684 (68%) isolates originated from adult outpatients and remaining 1236 (32%) isolates from pediatric patients. Of these 2783 isolates were from enterobacteriaceae family. Out of these 2730 (98.1%) were sensitive to fosfomycin. Most [375 of 385 (97.4%)] Pseudomonas spp were also susceptible to fosfomycin. A majority of ESBL- (96.5%) and MBL (91.9%)-producing isolates were also susceptible to fosfomycin and so were of Gram-positive isolates [698/707 (96%)] and MRSA [61/69 (88.4%)] were susceptible to fosfomycin. Conclusions Fosfomycin showed an excellent in vitro activity against all urinary pathogens, including the Gram-positive or Gram-negative, ESBL and MBL producers. Fosfomycin should be considered as a highly effective alternative in treatment UTIs in both adults and pediatric patients.
机译:摘要介绍细菌抗性的增加和新型抗微生物剂的有限选择需要重新引入一些旧抗菌剂。其中一种药物是福赛霉素,但其潜力尚未完全探讨,特别是在印度。目的和目的来分析氟霉素的体外活性,对尿液分离株,并将其与其他口服施用抗微生物剂的体外活性进行比较。材料和方法这是2014年7月至2016年6月至2016年7月至2016年6月的潜在观察研究。包括从所有年龄段和诊断有UTI的所有年龄和双年患者获得的所有连续,非重复和临床上重要的泌尿菌。排除了已经抗生素治疗的患者。通过半胱氨酸乳糖电解质缺陷介质的半定量方法进行尿培养,并根据CLSI指南,对显着计数中获得的分离物进行抗微生物敏感性测试。结果共有3947个非重复尿液分离株,其中2684(68%)分离物来自成人门诊患者,其余来自儿科患者的1236(32%)分离物。其中2783个分离物来自肠杆菌酸纤维系。其中2730(98.1%)对Fosfomcin敏感。大多数[385/375的385(97.4%)]假单胞菌SPP也易于福斯霉素。产生大部分ESBL-(96.5%)和MBL(91.9%)的分离物也易于氟哌霉素,因此革兰氏阳性分离物[698/707(96%)]和MRSA [61/69(88.4%) ]易于福斯福霉素。结论Fosfomycin对所有泌尿病原体表现出优异的体外活动,包括革兰氏阳性或革兰氏阴性,ESBL和MBL生产商。福斯福霉素应被视为成人和儿科患者的治疗utis中的高效替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号